Glucose Meter Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00782496 |
|
Recruitment Status :
Completed
First Posted : October 31, 2008
Results First Posted : November 30, 2010
Last Update Posted : February 29, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetes Mellitus | Device: Education + new meter Device: Education + new meter + feature activation | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 211 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A New Contour Blood Glucose Monitoring System With High Frequency Testing Patients |
| Study Start Date : | November 2008 |
| Actual Primary Completion Date : | September 2009 |
| Actual Study Completion Date : | September 2009 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Level1 Basic Meter Features
Adults with type 1 and type 2 diabetes use only basic features (Level 1) to test their blood. The CONTOUR meter has the basic features such as small meter size, easy to use , No Coding™ technology, 5-second test time, small sample size (0.6 µL), automatic control solution marking, 480 reading memory capacity.
|
Device: Education + new meter
Diabetes education and a new meter with basic features |
|
Experimental: Level 2 Advanced Meter Features
Adults with type 1 and type 2 diabetes additionally access and use more advanced meter features(Level 2)during blood glucose testing. The advanced features include ability to mark blood glucose values as obtained before or after meals or to set an audible reminder to test.
|
Device: Education + new meter + feature activation
Diabetes education and a new meter with advanced features |
- Average Number of Weekly Post-Prandial Blood Glucose Tests Performed by Subjects Using Either Basic or Advanced Meter Features [ Time Frame: 6 months ]
- Percent of Level 2 Participants Who Rated Helpfulness of Advanced Meter Features as 1 or 2 [ Time Frame: Over six month period ]Level 2 participants, who used advanced meter features, responded to questionnaires. They rated helpfulness of the meal marker reminder feature on a 5 point scale, 1 being strongly agree and 5 being strongly disagree.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Persons with type 1 or type 2 diabetes
- Persons who are on a pump or are taking at least 1 mealtime injection of insulin a day
- Persons at least 21 years of age
-
Persons willing to complete all study visits and study procedures including:
- Using the meal-marker + reminder feature regularly (Group 2 subjects only)
- Using the paper logbook provided (both Groups)
- Testing their BG at least 3 times a day during the entire study.
- Persons who are able to speak, read and understand English
- Persons who are currently performing self-testing of blood glucose at home routinely (at least 3 times per day) for 4 weeks or more
Exclusion Criteria:
- Persons who have been using a CONTOUR, BREEZE or BREEZE 2 meter regularly during the previous 6 months
- Persons who test over 6 times/day regularly
- Persons who wear a BG sensor 2 weeks or more during each month.
- Persons with home heath aides who assist with their BG testing.
-
Persons with the following impairments which, in the opinion of the investigator, would seriously compromise the integrity of the study:
- Significant visual impairment
- Significant hearing impairment
- Cognitive disorder
- Significant unstable co-morbidity (with notable change within the past 3 months)
- Any other condition as per investigator's discretion
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00782496
| United States, Georgia | |
| Atlanta Diabetes Associates | |
| Atlanta, Georgia, United States, 30309 | |
| United States, Minnesota | |
| International Diabetes Center | |
| Minneapolis, Minnesota, United States, 55416 | |
| United States, New York | |
| Mount Sinai School of Medicine | |
| New York City, New York, United States, 10029 | |
| United States, Washington | |
| University of Washington Medical Center/Diabetes Care Center | |
| Seattle, Washington, United States, 98105 | |
| Principal Investigator: | Dace Trence, MD | University of Washington Medical Center/Diabetes Care Center | |
| Principal Investigator: | Bruce W Bode, MD | Atlanta Diabetes Associates | |
| Principal Investigator: | Ronald Tamler, MD, Phd, MBA | Icahn School of Medicine at Mount Sinai | |
| Principal Investigator: | Richard M Bergenstal, MD | International Diabetes Center at Park Nicollet |
| Responsible Party: | Ascensia Diabetes Care |
| ClinicalTrials.gov Identifier: | NCT00782496 |
| Other Study ID Numbers: |
CTD-2008-09 |
| First Posted: | October 31, 2008 Key Record Dates |
| Results First Posted: | November 30, 2010 |
| Last Update Posted: | February 29, 2016 |
| Last Verified: | January 2016 |

